Skip to main content
Figure 2 | Cancer Imaging

Figure 2

From: Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

Figure 2

Representative18F-FDG-PET/CT images showing progression in a patient without an exon 11 KIT mutation (a-d) and response in a patient with an exon 11 KIT mutation (e-h) at baseline (a-b, e-f) and after 1 month of therapy (c-d, g-h). Red arrows point to sites of disease. Reprinted with permission. © (2013) American Society of Clinical Oncology. All rights reserved. From: Hodi S, et al. J Clin Oncol. 31(26), 2013:3182-3190.

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us